Home » Stocks » CWBR

CohBar, Inc. (CWBR)

Stock Price: $1.40 USD -0.03 (-2.10%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $1.42 +0.02 (1.43%) Jan 15, 5:00 PM
Market Cap 85.56M
Revenue (ttm) n/a
Net Income (ttm) -15.27M
Shares Out 50.20M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.40
Previous Close $1.43
Change ($) -0.03
Change (%) -2.10%
Day's Open 1.43
Day's Range 1.39 - 1.44
Day's Volume 327,634
52-Week Range 0.87 - 4.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

MENLO PARK, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...

GlobeNewsWire - 1 month ago

MENLO PARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...

Seeking Alpha - 2 months ago

CohBar, Inc. (CWBR) CEO Steve Engle on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

GlobeNewsWire - 2 months ago

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

Zacks Investment Research - 2 months ago

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: CI, DRRX, GRFS, PTI
GlobeNewsWire - 2 months ago

MENLO PARK, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...

GlobeNewsWire - 2 months ago

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...

GlobeNewsWire - 2 months ago

Company to host a Key Opinion Leader webinar on the current treatment landscape in IPF, the unmet need, and positive findings from preclinical studies of CohBar's CB5138 Analogs on Friday, Nov...

GlobeNewsWire - 3 months ago

MENLO PARK, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...

GlobeNewsWire - 3 months ago

MENLO PARK, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...

GlobeNewsWire - 3 months ago

MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...

GlobeNewsWire - 3 months ago

MENLO PARK, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic disease...

GlobeNewsWire - 4 months ago

MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic disease...

GlobeNewsWire - 4 months ago

MENLO PARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic disease...

GlobeNewsWire - 4 months ago

MENLO PARK, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat ...

GlobeNewsWire - 4 months ago

MENLO PARK, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat ...

GlobeNewsWire - 4 months ago

MENLO PARK, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat ...

GlobeNewsWire - 4 months ago

MENLO PARK, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases...

Seeking Alpha - 5 months ago

CohBar, Inc. (CWBR) CEO Steve Engle on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

New positive preliminary preclinical results in ARDS model Company to host conference call and webcast at 5:00 p.m. ET

GlobeNewsWire - 5 months ago

In vivo data demonstrates antifibrotic effects of multiple novel peptide analogs in preclinical models of idiopathic pulmonary fibrosis (IPF) In vivo data demonstrates antifibrotic effects of ...

GlobeNewsWire - 5 months ago

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

GlobeNewsWire - 6 months ago

MENLO PARK, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases...

GlobeNewsWire - 6 months ago

MENLO PARK, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases...

GlobeNewsWire - 6 months ago

MENLO PARK, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases...

GlobeNewsWire - 7 months ago

MENLO PARK, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases ...

Seeking Alpha - 8 months ago

CohBar, Inc. (CWBR) CEO Steve Engle on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

Former senior executive to continue on CohBar Board of Directors Former senior executive to continue on CohBar Board of Directors

Seeking Alpha - 8 months ago

CohBar Looks Undervalued Ahead Of Upcoming Data Readout

GlobeNewsWire - 8 months ago

Preclinical Testing of CB5064 Analogs Initiated in ARDS Preclinical Testing of CB5064 Analogs Initiated in ARDS

GlobeNewsWire - 8 months ago

MENLO PARK, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases ...

GlobeNewsWire - 9 months ago

COVID-19 Pandemic Impact at Clinical Sites Delays Study COVID-19 Pandemic Impact at Clinical Sites Delays Study

Seeking Alpha - 10 months ago

CohBar's (CWBR) CEO Steve Engle on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Anti-tumor effects demonstrated in vivo in preclinical melanoma immuno-oncology model Anti-tumor effects demonstrated in vivo in preclinical melanoma immuno-oncology model

GlobeNewsWire - 1 year ago

New results also confirm anti-inflammatory effect New results also confirm anti-inflammatory effect

Seeking Alpha - 1 year ago

CohBar's (CWBR) CEO Steve Engle on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

CohBar - The Pioneer In Mitochondrial Drugs

GlobeNewsWire - 1 year ago

MENLO PARK, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related dise...

GlobeNewsWire - 1 year ago

MENLO PARK, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related dise...

GlobeNewsWire - 1 year ago

MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related dis...

Seeking Alpha - 1 year ago

CohBar, Inc. (CWBR) CEO Steven Engle on Q2 2019 - Earnings Call Transcript

Seeking Alpha - 1 year ago

CohBar Inc. (CWBR) Interim CEO Philippe Calais on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

CohBar Inc. (CWBR) CEO Philippe Calais on Q4 2018 Results - Earnings Call Transcript

About CWBR

CohBar, a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, w... [Read more...]

Industry
Biotechnology
Founded
2007
CEO
Steven B. Engle M.S.
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
CWBR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CohBar stock is "Strong Buy." The 12-month stock price forecast is 6.38, which is an increase of 355.71% from the latest price.

Price Target
$6.38
(355.71% upside)
Analyst Consensus: Strong Buy